Of course, you are entitled to your opinion. However, there is no information available that a partnership is in the works, and further it is very unlikely that "big pharma" would be such a partner. Most big pharma have exited the device business. Even with a partner, the data is unlikely to impressive to the medical community until they do a larger. more well controlled trial that can be published. How do we know this? We have already seen a similar device that is on the market in the EU have data published in JAMA. That data demonstrated efficacy, including survival but the patient numbers were too small to have a significant effect on sales.
New potential investors should do careful diligence here. There are many frantic posters that would like to convince you that this device is so novel that it is a "game changer:. The reality is that we already have a perfect test market with the competitor's device. Could the CTSO device be beter? Yes, but that has to be proven and the current study does not even address that question.
Market Data 
Markets 
AI
